Press Releases

Date Title
Toggle Summary vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- vTv Therapeutics Inc. ( vTv Therapeutics ) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017 . “We’ve made significant progress in the third quarter of 2017
View HTML
Toggle Summary vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 30, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical
View HTML
Toggle Summary vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that additional analysis from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes will be
View HTML
Toggle Summary JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
vTv Therapeutics and JDRF enter into a $6 million industry partnership to explore the effect of liver-selective glucokinase activator TTP399 as an insulin-adjunctive therapy in type 1 diabetes HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 6, 2017-- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation
View HTML
Toggle Summary vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 2, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter ended June 30, 2017 . “With positive progress in our lead Alzheimer’s and diabetes programs, vTv is
View HTML
Toggle Summary vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 13, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017
View HTML
Toggle Summary vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small
View HTML
Toggle Summary vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced
View HTML
Toggle Summary vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST
View HTML